News
Aeterna Buys Promising Immunosuppressive Therapy Platform for NMOSD
neuromyelitisnews.com
Aeterna Zentaris has acquired exclusive global rights to develop and market autoimmune modifying proteins for the treatment of NMOSD.
sortiert nach Relevanz / Datum